Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

FREDUN PHARMACEUTICALS LTD.

NSE : NABSE : 539730ISIN CODE : INE194R01017Industry : Pharmaceuticals & DrugsHouse : Private

BSE2325.2514 (+0.61 %)

PREV CLOSE ( ) 2311.25

OPEN PRICE ( ) 2335.00

BID PRICE (QTY) 2325.25 (7)

OFFER PRICE (QTY) 2345.90 (8)

VOLUME 5828

TODAY'S LOW / HIGH ( )2311.00 2375.00

52 WK LOW / HIGH ( ) 707.92620

NSE

This Company is not listed in NSE

Select year

Particulars

Mar 2026

Mar 2025

Operational & Financial Ratios

Earnings Per Share (Rs)

59.61

41.80

CEPS(Rs)

74.68

52.48

DPS(Rs)

0.70

Book NAV/Share(Rs)

482.77

299.43

Tax Rate(%)

30.59

28.20

Margin Ratios

Core EBITDA Margin(%)

14.31

11.56

EBIT Margin(%)

13.58

10.99

Pre Tax Margin(%)

7.40

6.06

PAT Margin (%)

5.13

4.35

Cash Profit Margin (%)

6.43

5.46

Performance Ratios

ROA(%)

5.78

4.05

ROE(%)

16.09

13.96

ROCE(%)

21.34

16.16

Asset Turnover(x)

1.13

0.93

Sales/Fixed Asset(x)

5.71

6.09

Working Capital/Sales(x)

3.16

4.58

Efficiency Ratios

Fixed Capital/Sales(x)

0.18

0.16

Receivable days

77.49

142.46

Inventory Days

146.38

192.94

Payable days

93.37

160.10

Valuation Parameters

PER(x)

28.05

15.99

PCE(x)

22.39

12.74

Price/Book(x)

3.46

2.23

Yield(%)

0.04

0.10

EV/Net Sales(x)

1.69

1.05

EV/Core EBITDA(x)

11.34

8.70

EV/EBIT(x)

12.42

9.58

EV/CE(x)

2.14

1.55

M Cap / Sales

1.44

0.70

Growth Ratio

Net Sales Growth(%)

40.03

0.00

Core EBITDA Growth(%)

72.22

0.00

EBIT Growth(%)

73.08

0.00

PAT Growth(%)

65.26

0.00

EPS Growth(%)

42.59

0.00

Financial Stability Ratios

Total Debt/Equity(x)

0.84

1.18

Current Ratio(x)

1.68

1.30

Quick Ratio(x)

0.77

0.57

Interest Cover(x)

2.20

2.23

Total Debt/Mcap(x)

0.24

0.53